Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2001
10/04/2001WO2001072737A1 Triarylimidazole derivatives as cytokine inhibitors
10/04/2001WO2001072728A2 Novel piperazine derivatives
10/04/2001WO2001072723A1 Oxa(thia)zolidine derivative and anti-inflammatory drug
10/04/2001WO2001072720A1 Bicyclic amine derivatives as inhibitors of class 1 receptor tyrosine kinases
10/04/2001WO2001072718A1 Pharmaceutical compositions containing as the active ingredient nitropyrimidine derivatives or salts thereof
10/04/2001WO2001072717A1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
10/04/2001WO2001072714A2 Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
10/04/2001WO2001072711A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
10/04/2001WO2001072707A2 Carbamate caspase inhibitors and uses thereof
10/04/2001WO2001072705A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors
10/04/2001WO2001072703A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
10/04/2001WO2001072702A2 Amidino compounds useful as nitric oxide synthase inhibitors
10/04/2001WO2001072692A1 Malonamic acids and derivatives thereof as thyroid receptor ligands
10/04/2001WO2001072669A2 Therapeutic use of polyhydroxy amine derivates
10/04/2001WO2001072335A2 Methods for effecting neuroprotection using a potassium channel modulator
10/04/2001WO2001072328A2 Methods of treating diseases with activated protein c
10/04/2001WO2001072311A1 Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death
10/04/2001WO2001072310A1 Pharmaceutical gel composition
10/04/2001WO2001072309A2 Treatment of cerebrovascular disease
10/04/2001WO2001072308A1 Composition and method for intervening neuronal death using sulfasalazine
10/04/2001WO2001072301A1 Intracorporeal medicaments for photodynamic treatment of disease
10/04/2001WO2001072281A2 Microspheres for active embolization
10/04/2001WO2001072279A2 Medical emulsion for lubrication and delivery of drugs
10/04/2001WO2001047878A8 Substituted pyrrole mannich bases to combat pain and allergic reactions
10/04/2001WO2001036602A3 Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same
10/04/2001WO2001032070A3 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
10/04/2001WO2001023563A3 Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
10/04/2001WO2001022959A3 Compositions comprising progesterone or progesterone analogs for the treatment of inflammatory conditions
10/04/2001WO2001021773A3 Human endothelin converting enzyme-like proteins and polynucleotides encoding the same
10/04/2001WO2001019828A3 Kinase inhibitors as therapeutic agents
10/04/2001WO2001019361A3 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate
10/04/2001WO2001016319A3 Compositions and methods for the treatment of immune related diseases
10/04/2001WO2001005764A3 Sulfuric acid mono-[3-({1- [2-(4-fluoro-phenyl)-ethyl]- piperidin-4-yl}- hydroxy- methyl)-2- methoxy-phenyl]ester
10/04/2001WO2000062795A9 UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS
10/04/2001WO2000043039A9 Vaccine-mediated treatment of neurological disorders
10/04/2001WO2000039279A9 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
10/04/2001US20010027216 Method for preventing hormone induced adverse effects
10/04/2001US20010027212 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
10/04/2001US20010027211 Anticarcinogenic, -inflammatory and -proliferative agents; viricides; bactericides; vascular restenosis, autoimmune diseases; psoriasis; anticolesterol and -lipemic agents
10/04/2001US20010027207 Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation; anticarcinogenic, -diabetic, -proliferative and -inflammatory agents; vascular system disorders
10/04/2001US20010027196 Adenosine receptor ligands and their use in the treatment of disease
10/04/2001US20010027184 Serine/threonine protein kinase (H-SGK2)
10/04/2001US20010027181 Treatment or prophylaxis of ischemic heart disease
10/04/2001US20010027176 Cyclooxygenase inhibitor
10/04/2001US20010026814 Composition for and method of reducing low density lipoprotein cholesterol concentration
10/04/2001US20010026813 Treatment and prophylaxis of brain disorders, Alzheimer's and Parkinson disease, apoplexy; nontoxic
10/04/2001US20010026794 Two heterologous DNA encoding gene products; prolonged half-life
10/04/2001EP1138692A1 Fragments of human chorionic gonadotropin (hcg) as immunoregulator
10/04/2001EP1138680A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
10/04/2001EP1138678A2 Process for making N-((4-phenyl) methylphenyl) piperazines
10/04/2001EP1138329A2 Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions
10/04/2001EP1137948A1 Methods and compositions to lower plasma cholesterol levels
10/04/2001EP1137805A1 Methods of facilitating vascular growth
10/04/2001EP1137773A2 Growth factor homolog zvegf3
10/04/2001EP1137771A2 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
10/04/2001EP1137762A1 Treatment of pompe's disease
10/04/2001EP1137671A1 Reaction products of hyaluronic acid and natural amino acids and their use in cosmetic and pharmaceutical compositions
10/04/2001EP1137667A2 Analogues of glp-1
10/04/2001EP1137666A1 Glp-1 analogues
10/04/2001EP1137665A1 Cark protein and nucleic acid molecules and uses therefor
10/04/2001EP1137662A1 Pharmaceutical compositions comprising quinapril magnesium
10/04/2001EP1137661A1 Procollagen c-proteinase inhibitors
10/04/2001EP1137659A1 Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof
10/04/2001EP1137656A1 31 human secreted proteins
10/04/2001EP1137653A1 Troxerutin with high trihydroxy-ethyl-rutin content and method for preparing same
10/04/2001EP1137644A1 Benzofuran derivatives, their preparation and use
10/04/2001EP1137642A1 Bis-sulfonamides
10/04/2001EP1137640A1 Cyclic hydrazine derivatives as tnf-alpha inhibitors
10/04/2001EP1137631A1 REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE
10/04/2001EP1137621A1 Aldose reductase inhibitors and pharmaceutical compositions
10/04/2001EP1137497A1 Apparatus for separating particles of cohesive material according to size and process
10/04/2001EP1137438A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors
10/04/2001EP1137417A1 Use of selected modulators of p2 purinoceptors for the prevention of damage and mortality caused by global cerebral ischemia and ischemia-reperfusion
10/04/2001EP1137415A1 Myt1 kinase inhibitors
10/04/2001EP1137410A1 Novel 4-dedimethy laminotetra cycline derivatives
10/04/2001EP1137409A2 Compositions and methods for amelioration of human female sexual dysfunction
10/04/2001EP1137408A1 Agent for lowering endothelin levels
10/04/2001EP1137402A1 Phospholipid compositions
10/04/2001EP1123094A4 Therapeutic compositions (ii)
10/04/2001EP1079852B1 Composition based on pentoxifylline and anticytokin
10/04/2001EP0975631B1 5-aryl-3-(8-azabicyclo[3.2.1]oct-3-yl)-1,3,4-oxadiazol-2(3h)-one derivatives as 5-ht4 receptor ligands
10/04/2001EP0891326B1 Novel vitamin d analogues
10/04/2001EP0853614B1 Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
10/04/2001EP0842174B1 Heterocyclic compounds for treating myocardial ischaemia
10/04/2001EP0830350B1 n-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1h-benzo[b][1,5]diazepin-3-yl)-acetamides
10/04/2001EP0821665B1 Cyclobutane derivatives as inhibitors of squalene synthase and protein farnesyltransferase
10/04/2001EP0815123B1 Beta-sheet mimetics and use thereof as protease inhibitors
10/04/2001EP0809635B1 Alpha-substituted hydrazides having calpain inhibitory activity
10/04/2001EP0802909B1 Substituted oxazolidine calpain and/or cathepsin b inhibitors
10/04/2001EP0730581B1 3-acylaminobenzazepines
10/04/2001EP0639979B1 LIGAND FOR THE c-KIT RECEPTOR AND METHODS OF USE THEREOF
10/04/2001EP0613465B1 1,3-substituted cycloalkenes and cycloalkanes as central nervous system agents
10/04/2001EP0552329B1 Methylen-oxindole derivatives and process for their preparation
10/04/2001DE19947154A1 Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
10/04/2001CA2429196A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
10/04/2001CA2404901A1 Composition and method for intervening neuronal death using sulfasalazine
10/04/2001CA2404662A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
10/04/2001CA2404626A1 Novel piperazine derivatives
10/04/2001CA2404532A1 Method of identifying inhibitors of tie-2
10/04/2001CA2404528A1 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
1 ... 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 ... 1595